Moderna, Inc.
NASDAQModerna heads into Wednesday's first-quarter release with analysts freshly raising targets — yet none willing to turn bullish. The most striking feature of the run-up is the breadth and speed of analyst target upgrades on Monday alone. Goldman Sachs lifted its target from $43 to $49, while Evercore ISI jumped from $35 to $50, and UBS moved from $36 to $45. All three maintained neutral or in-line…
Snapshot as of 7 May 2026
Moderna heads into Wednesday's first-quarter release with analysts freshly raising targets — yet none willing to turn bullish. The most striking feature of the run-up is the breadth and speed of analyst target upgrades…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for MRNA — free to start on ORTEX.
Sign up for free →Open MRNA on ORTEX